IMNM — Immunome Inc
NASDAQ · Healthcare · Biotechnology
$27.16
+$0.09 (+0.35%)
Immunome Inc (IMNM) is a biotechnology company listed on NASDAQ. It is led by Clay B. Siegall Ph.D., based in 18702 North Creek Parkway, Bothell, WA, United States, 98011, with about 206 employees. Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Latest reported IMNM revenue for 2025-09-30 was $0. Net income was -$142.5M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. IMNM currently screens at market cap $2.47B.
Use this IMNM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMNM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMNM SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunome Inc even when a live quote feed is slow.
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Key Statistics
Market Cap
$2.47B
Volume
978,437
Previous Close
$28.52
Day Range
$27.64 – $28.85
EPS
-$5.00
Revenue
$9.04M
Net Income
-$292.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-35.5%
Profit Margin
-3240.4%
Employees
206
IMNM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.04M | $14.02M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$292.96M | -$106.81M | -$36.90M | -$24.71M |
| EPS (Diluted) | -$5.00 | -$5.38 | -$3.09 | -$2.14 |
Total Assets
$240.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$143.35M
Operating Cash Flow
-$110.79M
Free Cash Flow
$0.00
Immunome Inc Company Information
- Chairman, President & CEO
- Clay B. Siegall Ph.D.
- Headquarters
- 18702 North Creek Parkway, Bothell, WA, United States, 98011
- Website
- immunome.com
- Phone
- 425 939 7410
- IPO / Founded
- 2020-10-02
- Sector
- Healthcare
- Industry
- Biotechnology